Modulation of systemic and renal haemodynamics by κ-opioids in conscious lambs

Experimental Physiology

Volumn 91, Issue 5, 2006, Pages 877-885

  Qi, Wei ^a   Smith, Francine G ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 5' GUANIDINONALTRINDOLE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; NALTRINDOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG RESPONSE; HEART RATE; INSTRUMENTATION; KIDNEY BLOOD FLOW; LAMB; MEAN ARTERIAL PRESSURE; NONHUMAN; POSTNATAL DEVELOPMENT; VENOUS PRESSURE;

EID: 33747600638     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2006.033456     Document Type: Article

References (44)

1. Bachelard H & Pitre M (1995). Regional haemodynamic effects of μ-, and δ-, and κ-opioid agonists microinjected into the hypothalamic paraventricular nuclei of conscious, unrestrained rats. Br J Pharmacol 115, 613-621.
2. Barg J, Levy R & Simantov R (1989). Expression of the three opioid receptor subtypes mu, delta and kappa in guinea pig and rat brain cell cultures and in vivo. Int J Dev Neurosci 7, 173-179.
3. Barg J & Simantov R (1989). Developmental profile of kappa, mu and delta opioid receptors in the rat and guinea pig cerebellum. Dev Neurosci 11, 428-434.
4. de Wildt SN & Smith FG (1997). Effects of the angiotensin converting enzyme (ACE) inhibitor, captopril, on the cardiovascular, endocrine and renal responses to furosemide in conscious lambs. Can J Physiol Pharmacol 75, 263-270.
5. Broadbear JH, Negus SS, Butelman ER, De Costa BR & Woods JH (1994). Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on κ-opioid agonists in the mouse writing assays. Psychopharmacology 115, 311-319.
6. Butelman ER, Ko M-C, Sobcyzk-Kojiro K, Mosberg HI, van Bemmel B, Zernig G & Woods JH (1998). Kappa-opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception. J Pharmacol Exp Ther 285, 595-601.
7. Carter DA & Lightman SL (1985). Selective cardiovascular and neuroendocrine effects of a κ-opioid agonist in the nucleus tractus solitarii of rats. J Physiol 367, 363-375.
8. Clark JA, Liu L, Price M, Hersh B, Edelson M & Pasternack GW (1989). Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype. J Pharmacol Exp Ther 251, 461-468.
9. Connell JMC, Whitworth JA, Davies DL, Lever AF, Richards AM & Fraser R (1987). Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertension 5, 425-433.
10. Endoh T, Matsuura H, Tanaka C & Nagase H (1992). Nor-binaltorphimine: a potent and selective κ-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 316, 30-42.
11. Feuerstein G & Faden AI (1984). Cardiovascular effects of dynorphin A-(1-8), dynorphin A-(1-13) and dynorphin A-(1-17) microinjected into the preoptic medialis nucleus of the rat. Neuropeptides 5, 295-298.
12. Goldstein A (1976). Opioid peptides (endorphins) in pituitary and brain. Science 193, 1081-1086.
13. Gottlieb HB, Varner KJ, Kenigs VA, Cabral AM & Kapusta DR (2005). Differential cardiovascular and renal responses produced by microinjection of the κ-opioid U-50488H [trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl]-benzene-acetamide) methane sulfonate] into subregions of the paraventricular nucleus. J Pharmacol Exp Ther 312, 678-685.
14. Gulati A & Bhargava HN (1988). Cardiovascular responses to opioid agonists in intact and adrenal demedullated rats. Eur J Pharmacol 156, 247-257.
15. Hall ED, Wolf DL & McCall RB (1988). Cardiovascular depressant effects of the kappa opioid receptor agonists U50488H and spiradoline mesylate. Circ Shock 26, 409-417.
16. Jewett DC, Grace MK, Jones RM, Billington CJ, Portoghese PS & Levine AS (2001). The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats. Brain Res 909, 75-80.
17. Jones RM & Portoghese PS (2000). 5′-Guanidinonaltrindole, a highly selective and potent κ-opioid receptor antagonist. Eur J Pharmacol 396, 49-52.
18. Kapusta DR (1995). Opioid mechanisms controlling renal function. Clin Exp Pharmacol Physiol 22, 891-902.
19. Kapusta DR, Jones SY & DiBona GF (1989). Role of renal nerves in excretory responses to administration of kappa agonists in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 251, 230-237.
20. Keshet E, Polakiewicz RD, Itin A, Ornoy A & Rosen H (1989). Proenkephalin A is expressed in mesodermal lineages during organogenesis. EMBO J 8, 2917-2923.
21. Kew D & Kilpatrick DL (1990). Widespread organ expression of the rat proenkephalin gene during early postnatal development. Mol Endocrinol 4, 337-340.
22. Kornblum HI, Hurlbut DE & Leslie FM (1987). Postnatal development of multiple opioid receptors in rat brain. Dev Brain Res 37, 21-41.
23. Lahti RA, Vonvoigtlander PF & Barsuhn C (1982). Properties of a selective kappa agonist, U-50,488H. Life Sci 31, 2257-2260.
24. Le Moine C, Fauchey V & Jaber M (2002). Opioid receptor gene expression in dopamine transporter knock-out mice in adult and during development. Neurosci 112, 131-139.
25. Mansour A, Burke S, Pavlic RJ, Akil H & Watson SJ (1996). Immunohistochemical localization of the cloned 1 receptor in the rat CNS and pituitary. Neurosci 71, 671-690.
26. Mansour A, Khachaturian H, Lewis ME, Akil H & Watson SJ (1988). Anatomy of CNS opioid receptors. Trends Neurosci 11, 308-314.
27. Negus SS, Mello NK, Linsenmayer DC, Jones RM & Portoghese PS (2002). Kappa opioid antagonist effects of the novel kappa antagonist 5′guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology 163, 412-419.
28. Nishi M, Takeshima H, Fukuda K, Kato S & Mori K (1993). cDNA cloning and pharmacological characterization of an opioid receptor with high affinities for κ-subtype-selective ligands. FEBS Lett 330, 77-80.
29. Pfeiffer A, Pasi A, Mehraein P & Herz A (1981). A subclassification of κ-sites in human brain by use of dynorphin 1-17. Neuropeptides 2, 89-97.
30. Pfeiffer A, Pasi A, Mehraein P & Herz A (1982). Opiate receptor binding sites in human brain. Brain Res 248, 87-96.
31. Pittius CW, Kley N, Loeffler J-P & Höllt V (1987). Proenkephalin B messenger RNA in porcine tissues: characterization, quantification, and correlation with opioid peptides. J Neurochem 48, 586-592.
32. Pugsley MK (2004). The opioid receptor independent actions of kappa receptor agonists in the cardiovascular system. Curr Pharm Des 10, 2429-2444.
33. Rothman RB, Bykov V, de Costa BR, Jacobson AER, Ice KC & Brady LS (1990). Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides 11, 311-331.
34. Rutherford SD & Gundlach AL (1993). Opioid peptide gene expression in the nucleus tractus solitarius of rat brain and increases induced by unilateral cervical vagotomy: implications for role of opioid neurons in respiratory control mechanisms. Neuroscience 57, 797-810.
35. Smith FG & Abraham J (1995). Renal and renin responses to furosemide in conscious lambs during postnatal maturation. Can J Physiol Pharmacol 73, 107-112.
36. Spain JL, Roth BL & Coscia CJ (1985). Differential ontogeny of multiple opioid receptors (μ,δ,κ). J Neurosci 5, 584-588.
37. Stevens WC, Jones RM, Subramanian G, Metzger TG, Fergusobn DM & Portoghese PS (2000). Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J Med Chem 43, 2759-2769.
38. Strittmatter SM, Lynch DR & Snyder SH (1986). Differential ontogeny of rat brain peptidases: prenatal expression of enkephalin convertase and postnatal development of angiotensin-converting enzyme. Dev Brain Res 29, 207-215.
39. Szeto HH, Wu D, Yee JS, Soong Y, Fukida S & Taylor CT (1996). U50,488H-induced pressor effect in the ovine foetus is mediated by sympathetic activation and vasopressin. Eur J Pharmacol 309, 183-187.
40. Villiger JW, Taylor KM & Gluckman PD (1982). Ontogenesis of opiate receptors in regions of the ovine brain. Pediatr Pharmacol 2, 349-356.
41. Vonvoigtlander PF, Lahti RA & Ludens JH (1983). U-50,488: a selective and structurally novel non-mu (kappa) opioid agonist. J Pharmacol Exp Ther 224, 7-12.
42. Wolleman M, Benyhe S & Simon J (1993). The kappa-opioid receptor: evidence for the different subtypes. Life Sci 52, 599-611.
43. Zhang C & Moss IR (1995). Age-related μ, δ- and κ-opioid ligands in respiratory-related brain regions of piglets: effect of prenatal cocaine. Dev Brain Res 87, 188-193.
44. Zimlichman R, Gefel D, Eliahou H, Matas Z, Rosen B, Gass S, Ela C, Eilam Y, Vogel Z & Barg J (1996). Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats. Circulation 93, 1020-1025.